Tag: Pfizer

Business Healthcare & Pharmaceuticals News

Pfizer Acquires Metsera in $4.9 Billion Deal, Bolsters Obesity Drug Portfolio

pfizer news

Pfizer has announced a definitive agreement to acquire clinical-stage biopharmaceutical company Metsera in a deal valued at an initial $4.9 billion, with the potential for an additional $2.4 billion in milestone payments. The acquisition is a strategic move to re-enter the lucrative weight-loss drug market by adding Metsera’s next-generation obesity and cardiometabolic disease treatments, including promising oral and injectable therapies, to Pfizer’s pipeline.

Regulatory Approval Healthcare & Pharmaceuticals News Vaccines

FDA Approves Pfizer-BioNTech COVID-19 Vaccine for High-Risk Adults and Seniors

pfizer news

Pfizer and BioNTech’s updated COMIRNATY vaccine, targeting the LP.8.1 COVID-19 sublineage, gained FDA approval for use in seniors and high-risk individuals aged 5 to 64. The vaccine promises enhanced immune defense against current variants and is set for immediate distribution across the U.S.

Business News

Pfizer Reports Strong Q2 2025 Results, Raises Full-Year EPS Guidance

pfizer news

Pfizer delivered robust Q2 2025 results, reporting $14.7 billion in revenue (up 10% operationally) and $0.78 adjusted EPS. Key drivers included double-digit growth from Comirnaty, Paxlovid and Abrysvo. The company raised its full-year adjusted EPS guidance to $2.90–3.10 while reaffirming revenue outlook of $61.0–64.0 billion, underscoring strong commercial execution and cost-saving initiatives.

Clinical Trials News Oncology

Pfizer and Astellas Announce Landmark Survival Benefit with XTANDI in Prostate Cancer Trial

pfizer news

Pfizer and Astellas report groundbreaking Phase 3 EMBARK trial results showing XTANDI® (enzalutamide) plus leuprolide significantly improves overall survival in men with non-metastatic hormone-sensitive prostate cancer (nmHSPC) and high-risk biochemical recurrence. This marks the first time an androgen receptor inhibitor-based therapy has shown a definitive survival benefit in this specific patient population, offering new hope for extending lives through early and effective treatment.

Clinical Trials Cancer Healthcare & Pharmaceuticals News

Pfizer’s BRAFTOVI® Combination Regimen Halves Mortality Risk in BRAF V600E-Mutant Metastatic Colorectal Cancer

pfizer news

Pfizer’s BRAFTOVI® combination regimen has demonstrated a 51% reduction in the risk of death and a 47% decrease in disease progression for patients with BRAF V600E-mutant metastatic colorectal cancer, according to the pivotal Phase 3 BREAKWATER trial.

Healthcare & Pharmaceuticals Cancer Clinical Trials News

Astellas and Pfizer’s XTANDI® Demonstrates Significant Long-Term Survival Benefit in Metastatic Hormone-Sensitive Prostate Cancer

pfizer news

XTANDI® (enzalutamide), co-developed by Astellas and Pfizer, has shown a significant 30% reduction in risk of death over five years in metastatic hormone-sensitive prostate cancer (mHSPC) patients, marking it as the first androgen receptor inhibitor to demonstrate this long-term survival benefit.